公开(公告)号：DE3462136D1

公开(公告)日：1987-02-26

申请号：DE3462136

申请日：1984-11-26

Applicant: BASF AG

Inventor： FRANKE ALBRECHT DR ,  SPIEGLER WOLFGANG DR ,  SIEGEL HARDO DR ,  MUELLER CLAUS D DR ,  VON PHILIPSBORN GERDA DR ,  LENKE DIETER PROF DR ,  GRIES JOSEF DR

IPC: A61K31/34 ,  A61K31/341 ,  A61K31/38 ,  A61K31/381 ,  A61K31/40 ,  A61K31/41 ,  A61K31/415 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/495 ,  A61P9/06 ,  C07D207/32 ,  C07D207/333 ,  C07D213/50 ,  C07D231/12 ,  C07D307/46 ,  C07D333/22 ,  C07D409/12

公开(公告)号：AT17571T

公开(公告)日：1986-02-15

申请号：AT84102634

申请日：1984-03-10

Applicant: BASF AG

Inventor： FRANKE ALBRECHT DR ,  GRIES JOSEF DR ,  MUELLER CLAUS D DR ,  LENKE DIETER PROF DR

IPC: C07D211/52 ,  A61K31/13 ,  A61K31/445 ,  A61K31/451 ,  A61P9/06 ,  C07C67/00 ,  C07C213/00 ,  C07C217/32 ,  C07C313/00 ,  C07C323/25 ,  C07D211/44 ,  C07D295/08 ,  C07D295/092 ,  C07D303/22 ,  C07C93/06

公开(公告)号：DE3243158A1

公开(公告)日：1984-05-24

申请号：DE3243158

申请日：1982-11-23

Applicant: BASF AG

Inventor： SCHLECKER RAINER DR ,  SCHMIDT PETER DR ,  THIEME PETER C DR ,  LENKE DIETER PROF DR ,  TESCHENDORF HANS-JUERGEN DR ME ,  TRAUT MARTIN DR ,  MUELLER CLAUS D DR MED ,  HOFMANN HANS PETER DR ,  KREISKOTT HORST PROF DR

IPC: A61K31/35 ,  A61K31/352 ,  A61K31/365 ,  A61K31/37 ,  A61P25/18 ,  A61P25/24 ,  A61P25/26 ,  A61P37/08 ,  A61P43/00 ,  C07D311/08 ,  C07D311/16 ,  C07D311/78 ,  C07D311/80

Abstract: Sulfonates of hydroxycoumarins of the formula I (I) where R1 and R2 are identical or different and are each hydrogen, halogen or alkyl of 1 to 5 carbon atoms which can be substituted by -NR4R5, -OR4 or -OC(O)R4, where R4 and R5 are identical or different and are each hydrogen or alkyl of 1 to 4 carbon atoms, or R1 and R2 are each a carboxylic acid group -OC(O)R4 or a carboxamido radical, with the proviso that R1 is not methyl when R2 is hydrogen, or R1 and R2 together form a -(CH2)n- chain where n is 3-5, and R3 is a straight-chain or branched alkyl radical of 1 to 8 carbon atoms or cycloalkyl of 3 to 8 carbon atoms, each of which can be substituted by halogen, -OR4, -NR4R5, -CN or phenyl, or R3 is a straight-chain or branched alkenyl radical of 3 to 8 carbon atoms, an amino group - NR4R5, or phenyl or naphthyl, each of which is unsubstituted or monosubstituted or polysubstituted by -OR4, -NR4R5, -NO2, halogen, -SR4, -S(O)R4, -OS(O)R4, -SCF3, -OS(O)CF3, -CN, -C(O)R4, -OC(O)R4, -NHC(O)R4, -CF3, C1-C4-alkyl or a combination of these substituents, a process for their preparation, drugs containing these compounds, and compounds of the formula I, in which R1 is methyl and R2 is hydrogen, for use as drugs.

公开(公告)号：GR73857B

公开(公告)日：1984-05-08

申请号：GR810164200

申请日：1981-02-20

Applicant: BASF AG

Inventor： MAY HANS-JOACHIM DR ,  LENKE DIETER PROF DR ,  GRIES JOSEF DR ,  TESCHENDORF HANS-JUERGEN DR ,  WORSTMANN WOLFGANG DR

IPC: C07D409/06 ,  A61K31/33 ,  A61K31/415 ,  A61K31/465 ,  A61K31/47 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P43/00 ,  C07D233/54 ,  C07D233/64 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

Abstract: 1-Aroyl-2-phenylamino-2-imidazolines of the general formula where R1 and R2 are identical or different and each is chlorine, bromine, fluorine, methyl, ethyl, methoxy, trifluoromethyl or cyano, R3 has the meanings given for R1 and R2 or is hydrogen and Ar is an unsubstituted or substituted monocyclic or bicyclic heteroaromatic radical containing 1, 2 or 3 nitrogen and/or oxygen and/or sulfur atoms, their salts with physiologically tolerated acids, their preparation, and drugs containing these compounds. The compounds have, inter alia, a blood pressure-reducing action.

公开(公告)号：DE3209158A1

公开(公告)日：1983-09-15

申请号：DE3209158

申请日：1982-03-13

Applicant: BASF AG

Inventor： ROSSY PHILLIP A DIPL CHEM DR ,  THYES MARCO DIPL CHEM DR ,  FRANKE ALBRECHT DIPL CHEM DR ,  KOENIG HORST PROF DIPL CHEM DR ,  GRIES JOSEF DR MED ,  LEHMANN HANS DIETER DR MED ,  LENKE DIETER PROF DR

IPC: C07D237/04 ,  C07D237/14 ,  A61K31/50

Abstract: Compounds of the general formula in which R denotes a hydrogen atom or the methyl, ethyl or propyl radical and R , if R denotes a hydrogen atom, denotes an alkenyl radical having 3 to 8 C atoms, which is optionally substituted by 1 to 3 halogen atoms, excluding the 1-methylvinyl radical, or, if R denotes the methyl, ethyl or propyl group, denotes an alkenyl radical having 2 to 8 C atoms, which is optionally substituted by 1 to 3 halogen atoms, and therapeutic compositions which contain these compounds.

公开(公告)号：DE3135617A1

公开(公告)日：1983-03-17

申请号：DE3135617

申请日：1981-09-09

Applicant: BASF AG

Inventor： ROSSY PHILLIP A DIPL CHEM DR ,  THYES MARCO DIPL CHEM DR ,  FRANKE ALBRECHT DIPL CHEM DR ,  KOENIG HORST PROF DIPL CHEM DR ,  GRIES JOSEF DR MED ,  LEHMANN HANS-DIETER DR MED ,  LENKE DIETER PROF DR

IPC: C07D237/26 ,  A61K31/50

Abstract: The present invention relates to diazabicyclo[4.2.0]octenones of the formula I, in which Y has the meaning given in the description, to their preparation and to their use as medicaments in the treatment of high blood pressure and for the therapy of thromboembolic disorders.

公开(公告)号：DE3135250A1

公开(公告)日：1983-03-17

申请号：DE3135250

申请日：1981-09-05

Applicant: BASF AG

Inventor： SCHLECKER RAINER DIPL CHEM DR ,  FRIEDRICH LUDWIG DR ,  LENKE DIETER PROF DR

IPC: A61K31/425 ,  A61K31/428 ,  A61P37/08 ,  C07D277/60 ,  C07D277/82 ,  C07D277/84

Abstract: Thiazolyloxamic acids and their derivatives of the general formula I processes for their preparation, and pharmaceutical formulations which contain these compounds and are useful as drugs for treating allergic disorders.

公开(公告)号：DE3044566A1

公开(公告)日：1982-07-15

申请号：DE3044566

申请日：1980-11-26

Applicant: BASF AG

Inventor： FRICKEL FRITZ-FRIEDER DIPL CHE ,  OSTERSEHLT BERND DIPL CHEM DR ,  FRANKE ALBRECHT DIPL CHEM DR ,  THYES MARCO DIPL CHEM DR ,  FRIEDRICH LUDWIG DR ,  GRIES JOSEF DR MED ,  LENKE DIETER PROF DR ,  WEIFENBACH HARALD DR

IPC: C07D233/54 ,  C07D233/61 ,  C07D233/64 ,  A61K31/415

Abstract: N-substd. imidazole derivs. of formula (I) and their salts with physiologically acceptable acids are new. (R1,R2 and R3 are each H, 1-8C alkyl or opt. substd. aralkyl; Alk is 2-8C alkylene opt. substd. with 1-3C alkyl gps.; R4 is O,S, =NR6, =CHNO2, or =CHR7R8; R5 is 2-((4-methyl-5-imidazolyl) methyl-thio) ethylamino; R6 is H, NO2, CN, carboxamido, 1-4C alkyl, aryl or arylsulphonyl; R7 and R8 are each nitrile or carboalkoxy). 12 cpds. (I) are specifically claimed, including N-cyano- N'-(2-((5-methyl- 1H-imidazol-4-yl)- methylthio)-ethyl)-N"-(3-(2-methylimidazol-1-yl) propyl) guanidine. (I) are selective Histamine-H2- antagonists and can be used in the treatment of illnesses associated with increased stomach acid production, e.g. stomach and duodenal ulcers. Suitable daily doses are 0.5-20 mg/kg p.o. and 0.05-10.0 mg/kg i.v.

公开(公告)号：DE3026331A1

公开(公告)日：1982-02-18

申请号：DE3026331

申请日：1980-07-11

Applicant: BASF AG

Inventor： FRANKE ALBRECHT DIPL CHEM DR ,  LENKE DIETER PROF DR ,  GRIES JOSEF DR MED ,  WEIFENBACH HARALD DR ,  KREISKOTT HORST DR ,  HOFMANN HANS PETER DR

IPC: C07D295/08 ,  A61K31/495 ,  A61P9/12 ,  A61P25/20 ,  C07C45/70 ,  C07D295/092 ,  C07D303/22 ,  C07D295/04

公开(公告)号：DE3022177A1

公开(公告)日：1982-01-07

申请号：DE3022177

申请日：1980-06-13

Applicant: BASF AG

Inventor： THYES MARCO DR ,  FRANKE ALBRECHT DR ,  KOENIG HORST PROF DR ,  LENKE DIETER PROF DR ,  LEHMANN HANS DIETER DR ,  GRIES JOSEF DR

IPC: A61K31/50 ,  A61P7/02 ,  A61P9/12 ,  C07D237/04

Abstract: -pyridazinone derivs. (I) are new. X is O or S; R1 is H or 1-3C alkyl; and R2 is 1-8C alkyl (opt. substd. by 1-4 halogen atoms, 1-4C alkoxy (sepd. from X by at least 2 C-atoms), 3-8C cycloalkyl (opt. carrying 1 or 2 1-3C alkyl gps.) or phenyl (opt. in turn carrying 1-3 substits. from 1-3C alkyl, 1-3C alkoxy, halogen, CF3 or NO2), 3-8C cycloalkyl (opt. mono- to tetra substd. by 1-4C alkyl), 3-8C alkenyl, 3-8C alkynyl or phenyl (opt. carrying 1-3 substits. from 1-4C alkyl, 1-4C alkoxy, halogen, CF3, CN and NO2). (I) have thrombocyte aggregation inhibiting and hypotensive properties. They can be used as antihypertensive agents and for the prophylaxis and treatment of thrombo-embolid diseases. Results of tests for pharmacological activity are given in the spec.